

## PERSONAL INFORMATION

**Anna Maria Frezza**✉ [annamaria.frezza@istitutotumori.mi.it](mailto:annamaria.frezza@istitutotumori.mi.it)**Date of birth** 3<sup>rd</sup> July 1984 | **Nationality** Italian

## WORK EXPERIENCE

11<sup>th</sup> January, 2016 - TodayMedical Oncologist at “Fondazione IRCCS Istituto Nazionale Tumori” – Adult Mesenchymal Tumours and Rare Cancers  
(Chief: Prof. Paolo G. Casali)<http://www.istitutotumori.mi.it/>

- Participation to all departmental activities including soft tissue and bone sarcoma patient care (both inpatients and outpatients), supervision of chemotherapy for sarcomas, attendance at multi-disciplinary meetings.
- Participation to national and international clinical studies in the field of soft tissue and bone sarcomas.
- Conduction of audits, clinical and translational research projects in the field of soft tissue and bone sarcoma. Participation in the coordination team of the EU Joint Action on Rare Cancers and in the coordination team of the European Reference Network for Rare Adult Cancers (EURACAN).
- Active involvement (scientific committee and faculty) in educational events in the field of soft tissue, GIST and bone sarcomas, held in collaboration with ESMO, ESO and University of Milan.

**Position held.** Medical oncologist.June 1<sup>st</sup> – December 31<sup>st</sup>, 2015Medical Oncologist at “Istituto Europeo di Oncologia – Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumour”  
(Chief: Dott. Nicola Fazio)<http://www.ieo.it/>

- Clinical management of neuroendocrine tumour patients, both as inpatients and outpatients; treatment administration and management of toxicity; participation to clinical case discussions during dedicated multidisciplinary group meeting (ENETS centre of excellence).
- Participation to national and international clinical studies in the field of neuroendocrine tumours.
- Clinical and translational research activities mainly in the field of neuroendocrine tumours.

**Position held.** Medical Oncologist.May 17<sup>th</sup>, 2010 – May 15<sup>th</sup>, 2015Medical Oncology trainee at “Università Campus Bio-Medico di Roma – Department of Medical Oncology”  
(Chief: Prof. Giuseppe Tonini)<http://www.unicampus.it/>

- Participation to all departmental activities including inpatient and outpatient cancer patient care, chemotherapy administration and side effects management, clinical case discussions within multidisciplinary team meetings.
- Clinical activity focused on management of soft tissue and bone sarcoma patients, treatment administration and management of toxicity, attendance to the dedicated multidisciplinary outpatient clinic. Active participation in the “Italian Rare Cancer Network”.
- Clinical and translational research activities in the field of soft tissue and bone sarcoma.

**Position held.** Trainee in Medical Oncology.June 1<sup>st</sup>, 2012 – November 30<sup>th</sup>, 2012Clinical and research fellow at “Royal Marsden Hospital – Soft Tissue Sarcoma Unit”  
(Chief: Prof. Ian Judson)<http://www.royalmarsden.nhs.uk/>

- Participation to all departmental activities including soft tissue and bone sarcoma patient care (both inpatients and outpatients), supervision of chemotherapy for sarcomas, attendance at multi-disciplinary meetings.
- Participation as a co-investigator to national and international clinical studies in the field of soft tissue and bone sarcomas
- Conduction of audits and clinical research projects.

**Position held.** Clinical and research fellow.September 1<sup>st</sup>, 2011 – May 31<sup>st</sup>, 2012Clinical and research fellow at “University College of London Hospital – The London Sarcoma Service”  
(Chief: Prof. Jeremy Whelan)<http://www.uclh.nhs.uk/>; <http://www.londonsarcoma.org/>

- Participation to all departmental activities including soft tissue and bone sarcoma patient care (both inpatients and outpatients), supervision of chemotherapy for sarcomas, attendance at multi-disciplinary meetings.
- Participation co-investigator to national and international clinical studies in the field of soft tissue and bone sarcomas.
- Conduction of audits, clinical and translational research projects. Coordination of international surveys, clinical trials design (IRCI, EORTC), participation to scientific collaboration within European societies (EMSOS).

**Position held.** Clinical and research fellow.

## TEACHING EXPERIENCE

December 2021	Faculty – 6th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers <a href="https://www.eso.net/en/events/future%2devents/online%2devent%3a%2d5th%2deso%2desmo%2drce%2dclinical%2dupdate%2don%2drare%2dadult%2dsolid%2dcancers/3-4734-0-">https://www.eso.net/en/events/future%2devents/online%2devent%3a%2d5th%2deso%2desmo%2drce%2dclinical%2dupdate%2don%2drare%2dadult%2dsolid%2dcancers/3-4734-0-</a>
December 2020	Faculty – 5th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers <a href="https://www.eso.net/en/events/future%2devents/online%2devent%3a%2d5th%2deso%2desmo%2drce%2dclinical%2dupdate%2don%2drare%2dadult%2dsolid%2dcancers/3-4734-0-">https://www.eso.net/en/events/future%2devents/online%2devent%3a%2d5th%2deso%2desmo%2drce%2dclinical%2dupdate%2don%2drare%2dadult%2dsolid%2dcancers/3-4734-0-</a>
February 2020	Faculty – ESMO Preceptorship Course “Sarcoma & GIST” <a href="https://www.esmo.org/meetings/past-meetings/esmo-sarcoma-gist-2020/programme">https://www.esmo.org/meetings/past-meetings/esmo-sarcoma-gist-2020/programme</a>
December 2019	Faculty – 4th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers <a href="https://www.eso.net/en/events/past%2devents/events%2d2019/4th%2deso%2desmo%2drce%2dclinical%2dupdate%2don%2drare%2dadult%2dsolid%2dcancers/3-4122-0-">https://www.eso.net/en/events/past%2devents/events%2d2019/4th%2deso%2desmo%2drce%2dclinical%2dupdate%2don%2drare%2dadult%2dsolid%2dcancers/3-4122-0-</a>
July 2019	Faculty – Residential Course – Clinical Oncology: Sarcomas First residential course on the multidisciplinary management of soft tissue sarcomas, GISTs and bone sarcomas, held in partnership with the “European School of Oncology”. <a href="https://www.eso.net/en/events/past%2devents/events%2d2019/residential-course-clinical-oncology:-sarcomas/3-3915-0-">https://www.eso.net/en/events/past%2devents/events%2d2019/residential-course-clinical-oncology:-sarcomas/3-3915-0-</a>
February 2018	Faculty – ESMO Preceptorship Course “Sarcoma & GIST” <a href="https://www.esmo.org/Conferences/Past-Conferences/Sarcoma-GIST-2018/Programme">https://www.esmo.org/Conferences/Past-Conferences/Sarcoma-GIST-2018/Programme</a>
January 2018	Faculty – University Post-graduate Course – Clinical Oncology: Sarcomas First post-graduate course on the multidisciplinary management of soft tissue sarcomas, GISTs and bone sarcomas, held in partnership with University of Milan and the “European School of Oncology”. <a href="https://www.eso.net/en/events/past-events/events-2018/university-post-graduate-course-clinical-oncology:-sarcomas/3-1473-0-">https://www.eso.net/en/events/past-events/events-2018/university-post-graduate-course-clinical-oncology:-sarcomas/3-1473-0-</a>
December 2017	Faculty – 2nd ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers <a href="https://www.eso.net/en/events/past-events/events-2017/2nd-eso-esmo-rce-clinical-update-on-rare-adult-solid-cancers/3-1397-0-">https://www.eso.net/en/events/past-events/events-2017/2nd-eso-esmo-rce-clinical-update-on-rare-adult-solid-cancers/3-1397-0-</a>
April 2015	Faculty - La pratica clinica nelle Neoplasie Neuroendocrine Enteropancreatiche. IEO Milano. <a href="https://www.ieo.it/Documents/IEO%20Education/Programma_NEN_PRECEPTORSHIP_2015.pdf?epslanguage=it">https://www.ieo.it/Documents/IEO%20Education/Programma_NEN_PRECEPTORSHIP_2015.pdf?epslanguage=it</a>
November 2008 – May 2015	Personal tutor for medical students – Facoltà di Medicina e Chirurgia, Università Campus Bio-Medico di Roma, Roma, Italia Prof. Sergio Morini, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Roma Personal tutoring for medical students (1° and 2° year) about study methodology, time management, self-confidence, career development.
2005-2006	Tutor in Human Anatomy – Facoltà di Medicina e Chirurgia, Università Campus Bio-Medico di Roma, Roma, Italia Prof. Sergio Morini, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Roma Tutorship in human anatomy for medical students (1° and 2° year) .
<b>EDUCATION AND TRAINING</b>	
May 17 <sup>th</sup> , 2010 – May 15 <sup>th</sup> , 2015	School of Medical Oncology, University Campus Bio-Medico, Rome, Italy Prof. Giuseppe Tonini, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Roma Final thesis: “Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study”. Final vote: 50/50 cum laude
4 <sup>th</sup> Aug-5 <sup>th</sup> September 2008	Clinical clerkship presso “Dana Farber Cancer Institute – Centre for Sarcoma and Bone Oncology” (Direttore: Dr. George Demetri)
September 1 <sup>st</sup> , 2003 – July 21 <sup>st</sup> , 2009	Medical School, University Campus Bio-Medico, Rome, Italy Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Roma Final thesis: “PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy”. Final vote: 110/110 summa cum laude
2006-2009	Internship in Medical Oncology, University Campus Bio-Medico, Rome, Italy

- 2005-2006 Prof. Giuseppe Tonini, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Roma  
 Internship in Human Anatomy, University Campus Bio-Medico, Rome, Italy
- 1998-2003 Prof. Sergio Morini, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, Roma  
 Scientific School "Bruno Tuschek", Grottaferrata, Italy  
 Liceo Scientifico Statale "Bruno Tuschek", Grottaferrata, Rome  
 Final vote: 100/100 summa cum laude

**EDUCATIONAL COURSES**

- 2017 ESMO 2017 - Leaders Generation Programme  
<https://www.esmo.org/Career-Development/Leaders-Generation-Programme/Class-of-2017>
- 2015 Grantsmanship course "How to write a winning grant application"  
 University of Milan, Milan (Italy)

**MEMBERSHIPS**

- European Society of Medical Oncology (ESMO)  
 Connective Tissue Oncology Society (CTOS)  
 Associazione Italiana Oncologia Medica (AIOM) – Italian Society of Medical Oncology  
 Italian Sarcoma Group (ISG)  
 American Society of Clinical Oncology (ASCO)

**SCIENTIFIC COMMITTEE**

**Italian Sarcoma Group (ISG)**

- Coordinator of the working group on education

**European Society of Medical Oncology (ESMO)**

- ESMO Press & Media Affairs Committee – member in 2017/2018
- ESMO Sarcoma Faculty (2017-2021)  
<https://www.esmo.org/content/download/102584/1812354/file/ESMO-Faculty-List.pdf>
- ESMO Annual Meeting 2021 – sarcoma track scientific committee  
<https://www.esmo.org/meetings/esmo-congress-2021/congress-officers/scientific-committee>
- "ESMO Open" – editorial board  
<https://esmoopen.bmj.com/pages/editorial-board/>

**MOTHER TONGUE**

Italian

**Other tongues**

	COMPREHENSION		SPEAKING		WRITING
	Listening	Reading	Interaction	Oral production	
English	Advanced	Advanced	Advanced	Advanced	Advanced

**CERTIFICATES**

- Cambridge Preliminary English Test (2001)
- Trinity Grade 5 (2001)
- Cambridge First certificate (2002)
- BLSA provider A.H.A. (2008, 2014)
- GCP training (2012, 2015, 2017; 2019, last 29 Jan 2021)

**SCIENTIFIC PRODUCTION**

SCOPUS ID: 22834268200  
 ORCID ID: 0000-0003-23357224  
 H-index Scopus: 21  
 H-index Google Scholar: 25

## PUBBLICATIONS

1. Weekly cisplatin with or without imatinib in advanced chordoma: A retrospective case-series analysis from the Italian Rare Cancers Network. Baldi GG, Lo Vullo S, Grignani G, Vincenzi B, Badalamenti G, Mastore M, Buonomenna C, Morosi C, Barisella M, **Frezza AM**, Provenzano S, Simeone N, Picozzi F, Mariani L, Casali PG, Stacchiotti S. *Cancer*. 2022 Jan 13.
2. Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution. Danieli M, Barretta F, Fiore M, Radaelli S, Sangalli C, Barisella M, Stacchiotti S, Palassini E, Miceli R, **Frezza AM**, Callegaro D, Casali PG, Gronchi A. *Ann Surg Oncol*. 2022 Jan 8.
3. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Blay JY, Hindi N, Bollard J, Aguiar S Jr, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro-Sánchez CHS, Carvajal B, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden V, Chacón M, Clara M, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati D, Dufresne A, Eriksson M, Farias-Loza M, Fernandez P, **Frezza AM**, Frisoni T, Garcia-Ortega DY, Gelderblom H, Gouin F, Gómez-Mateo MC, Gronchi A, Haro J, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes David BB, Lopez-Pousa A, Lutter G, Martinez-Said H, Martínez-Tlahuel J, Mello CA, Morales Pérez JM, Moura David S, Nascimento AG, Ortiz-Cruz EJ, Palmerini E, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Salas R, Santos TTG, Scotlandi K, Soule T, Stacchiotti S, Valverde C, Waisberg F, Zamora Estrada E, Martin-Broto J. *Cancer Treat Rev*. 2022 Jan;102:102312.
4. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, **Frezza AM**, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss SJ, Hall KS, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Gronchi A, Stacchiotti S; ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: [clinicalguidelines@esmo.org](mailto:clinicalguidelines@esmo.org). *Ann Oncol*. 2022 Jan;33(1):20-33.
5. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Strauss SJ, **Frezza AM**, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, de Álava E, Dei Tos AP, Garcia Del Muro X, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Gaspar N, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Gronchi A, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, López Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Ladenstein R, Casali PG, Stacchiotti S; ESMO Guidelines Committee, EURACAN, GENTURIS and ERN PaedCan. Electronic address: [clinicalguidelines@esmo.org](mailto:clinicalguidelines@esmo.org). *Ann Oncol*. 2021 Dec;32(12):1520-1536.
6. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up\*. Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, De Álava E, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, **Frezza AM**, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss S, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Casali PG, Stacchiotti S; ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: [clinicalguidelines@esmo.org](mailto:clinicalguidelines@esmo.org). *Ann Oncol*. 2021 Nov;32(11):1348-1365.
7. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. Stacchiotti S, Miah AB, **Frezza AM**, Messiou C, Morosi C, Caraceni A, Antonescu CR, Bajpai J, Baldini E, Bauer S, Biagini R, Bielack S, Blay JY, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Callegaro D, De Alava E, Deoras-Sutliff M, Dufresne A, Eriksson M, Errani C, Fedenko A, Ferraresi V, Ferrari A, Fletcher CDM, Garcia Del Muro X, Gelderblom H, Gladly RA, Gouin F, Grignani G, Gutkovich J, Haas R, Hindi N, Hohenberger P, Huang P, Joensuu H, Jones RL, Jungels C, Kasper B, Kawai A, Le Cesne A, Le Grange F, Leithner A, Leonard H, Lopez Pousa A, Martin Broto J, Merimsky O, Merriam P, Miceli R, Mir O, Molinari M, Montemurro M, Oldani G, Palmerini E, Pantaleo MA, Patel S, Piperno-Neumann S, Raut CP, Ravi V, Razak ARA, Reichardt P, Rubin BP, Rutkowski P, Safwat AA, Sangalli C, Sapisochin G, Sbaraglia M, Scheipl S, Schöffski P, Strauss D, Strauss SJ, Sundby Hall K, Tap WD, Trama A, Tweddle A, van der Graaf WTA, Van De Sande MAJ, Van Houdt W, van Oortmerssen G, Wagner AJ, Wartenberg M, Wood J, Zaffaroni N, Zimmermann C, Casali PG, Dei Tos AP, Gronchi A. *ESMO Open*. 2021 Jun;6(3):100170.
8. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Stacchiotti S, **Frezza AM**, Blay JY, Baldini EH, Bonvalot S, Bovee JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. *Cancer*. 2021 Aug 15;127(16):2934-2942.

9. Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network. **Frezza AM**, Napolitano A, Miceli R, Badalamenti G, Brunello A, Buonomenna C, Casali PG, Caraceni A, Grignani G, Gronchi A, Infante G, Morosi C, Saita L, Simeone N, Zaffaroni N, Vincenzi B, Stacchiotti S. *ESMO Open*. 2021 Mar 10;6(2):100083.
10. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. **Frezza AM**, Ravi V, Lo Vullo S, Vincenzi B, Tolomeo F, Chen TW, Teterycz P, Baldi GG, Italiano A, Penel N, Brunello A, Duffaud F, Hindi N, Iwata S, Smrke A, Fedenko A, Gelderblom H, Van Der Graaf W, Vozy A, Connolly E, Grassi M, Benjamin RS, Broto JM, Grignani G, Jones RL, Kawai A, Tysarowski A, Mariani L, Casali PG, Stacchiotti S. *Cancer Med*. 2021 Mar 13.
11. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives. Simeone N, **Frezza AM**, Zaffaroni N, Stacchiotti S. *Future Oncol*. 2020 Dec 8. doi: 10.2217/fon-2020-0781.
12. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Gelderblom H, Wagner AJ, Tap WD, Palmerini E, Wainberg ZA, Desai J, Healey JH, van de Sande MAJ, Bernthal NM, Staals EL, Peterfy CG, **Frezza AM**, Hsu HH, Wang Q, Shuster DE, Stacchiotti S. *Cancer*. 2020 Nov 16. doi: 10.1002/encr.33312.
13. Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian rare cancer network. Stacchiotti S, Simeone N, Lo Vullo S, Baldi GG, Brunello A, Vincenzi B, Palassini E, Dagrada G, Collini P, Morosi C, Greco FG, Sbaraglia M, Dei Tos AP, Mariani L, **Frezza AM**, Casali PG. *Cancer*. 2020 Oct 27. doi: 10.1002/encr.33247.
14. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review. Raimondi A, Simeone N, Guzzo M, Maniezzo M, Collini P, Morosi C, Greco FG, **Frezza AM**, Casali PG, Stacchiotti S. *ESMO Open*. 2020 Jul; 5(4):e000663. doi: 10.1136/esmopen-2019-000663.
15. The activity of chemotherapy in inflammatory myofibroblastic tumour (IMT): a multicentre, European retrospective case series analysis. Baldi GG, Brahmī M, Lo Vullo S, Cojocarū E, Mir O, Casanova M, Vincenzi B, De Pas T, Grignani G, Pantaleo MA, Blay JY, Jones RL, Le Cesne A, **Frezza AM**, Gronchi A, Collini P, Dei Tos AP, Morosi C, Mariani L, Casali PG, Stacchiotti S. *Oncologist*. 2020 Nov;25(11):e1777-e1784. doi: 10.1634/theoncologist.2020-0352.
16. Extraskeletal Myxoid Chondrosarcoma with Molecularly Confirmed Diagnosis: A Multicenter Retrospective Study Within the Italian Sarcoma Group. Paioli A, Stacchiotti S, Campanacci D, Palmerini E, **Frezza AM**, Longhi A, Radaelli S, Donati DM, Beltrami G, Bianchi G, Barisella M, Righi A, Benini S, Fiore M, Picci P, Gronchi A. *Ann Surg Oncol*. 2020 Jun 22. doi: 10.1245/s10434-020-08737-7.
17. The sacral chordoma margin. Radaelli S, Fossati P, Stacchiotti S, Akiyama T, Asencio JM, Bandiera S, Boglione A, Boland P, Bolle S, Bruland Ø, Brunello A, Bruzzi P, Campanacci D, Cananzi F, Capanna R, Casadei R, Cordoba A, Court C, Dei Tos AP, DeLaney TF, De Paoli A, De Pas TM, Desai A, Di Brina L, Donati DM, Fabbri N, Fiore MR, **Frezza A**, Gambarotti M, Gasbarrini A, Georg P, Grignani G, Hindi N, Hug EB, Jones R, Kawai A, Krol AD, Le Grange F, Luzzati A, Marquina G, Martin-Benlloch JA, Mazzocco K, Navarra F, Navarra P, Parchi PD, Patel S, Pennacchioli E, Petrongari MG, Picci P, Pollock R, Porcu L, Quagliuolo V, Sangalli C, Scheipl S, Scotto GM, Spalek M, Steinmeier T, Timmermann B, Trama A, Uhl M, Valverde C, Varga PP, Verges R, Weber DC, Zoccali C, Casali PG, Sommer J, Gronchi A. *Eur J Surg Oncol*. 2020 Aug;46(8):1415-1422. doi: 10.1016/j.ejso.2020.04.028.
18. Priorities on rare cancers' policy in National Cancer Control Plans (NCCPs): A review conducted within the framework of EU-JARC Joint-Action. Prades J, Weinman A, Le Cam Y, Trama A., **Frezza AM**, Borrás JM. *Journal of Cancer Policy*, Volume 24, June 2020, Article number 10022.
19. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Desmoid Tumor Working Group. *Eur J Cancer*. 2020 Mar;127:96-107. doi: 10.1016/j.ejca.2019.11.013.
20. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. **Frezza AM**, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desai I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetz S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S. *Cancer*. 2020 Jan 1;126(1):98-104. doi: 10.1002/encr.32508.
21. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, **Frezza AM**, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Blich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J. *Lancet Oncol*. 2019 Sep;20(9):1252-1262. doi: 10.1016/S1470-2045(19)30319-5.
22. Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in IN11-Negative Epithelioid Sarcoma Patient-Derived Xenograft. Stacchiotti S, Zucco V, Tortoreto M, Cominetti D, **Frezza AM**, Percio S, Indio V, Barisella M, Monti V, Blich S, Astolfi A, Colombo C, Pasquali S, Folini M, Gounder MM, Pantaleo MA, Collini P, Dei Tos AP, Casali PG, Gronchi A, Zaffaroni N. *Cancers (Basel)*. 2019 Jul 19;11(7):1015. doi: 10.3390/cancers11071015.
23. Management of complicated tumor response to tyrosine-kinase inhibitors in gastrointestinal stromal tumors. Tirota F, Fumagalli E, Colombo C, Morosi C, Barisella M, Radaelli S, **Frezza AM**, Casali PG, Gronchi A, Fiore M. *J Surg Oncol*. 2019 Aug;120(2):256-261. doi: 10.1002/jso.25491.
24. Chordoma: update on disease, epidemiology, biology and medical therapies. Frezza AM, Botta L, Trama A, Dei Tos AP, Stacchiotti S. *Curr Opin Oncol*. 2019 Mar;31(2):114-120. doi: 10.1097/CCO.0000000000000502.
25. Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. Stacchiotti S, Simeone N, Lo Vullo S, Morosi C, Greco FG, Gronchi A, Barisella M, Collini P, Zaffaroni N, Dagrada GP, **Frezza AM**, Mariani L, Casali PG. *Eur J Cancer*. 2019 Jan;106:225-233. doi: 10.1016/j.ejca.2018.10.024.
26. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Alava E, Dei Tos AP, Dei Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, **Frezza AM**, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN. *Ann Oncol*. 2018 Oct 1;29(Suppl 4):iv79-iv95. doi: 10.1093/annonc/mdy310.

27. Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. Stacchiotti S, Morosi C, Lo Vullo S, Casale A, Palassini E, **Frezza AM**, Dinoi G, Messina A, Gronchi A, Cavalleri A, Venturelli E, Morelli D, Pilotti S, Collini P, Brich S, Tamborini E, Mariani L, Casali PG. *Cancer*. 2018 Oct 15;124(20):4056-4063. doi: 10.1002/cncr.31685.
28. Survival of adults with cancers of bone or soft tissue in Europe-Report from the EUROCARE-5 study. Stiller CA, Botta L, Brewster DH, Ho VKY, **Frezza AM**, Whelan J, Casali PG, Trama A, Gatta G; EUROCARE-5 Working Group. *Cancer Epidemiol*. 2018 Oct;56:146-153. doi: 10.1016/j.canep.2018.08.010.
29. 2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma. **Frezza AM**, Lee ATJ, Nizri E, Sbaraglia M, Jones RL, Gronchi A, Dei Tos AP, Casali PG. *ESMO Open*. 2018 Jun 28;3(4):e000390. doi: 10.1136/esmooopen-2018-000390.
30. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, **Frezza AM**, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. *Ann Oncol*. 2018 Oct 1;29(Suppl 4):iv268-iv269. doi: 10.1093/annonc/mdy321.
31. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, **Frezza AM**, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. *Ann Oncol*. 2018 Oct 1;29(Suppl 4):iv68-iv78. doi: 10.1093/annonc/mdy095.
32. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. **Frezza AM**, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Tetrycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lohmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. *JAMA Oncol*. 2018 Sep 1;4(9):e180219. doi: 10.1001/jamaoncol.2018.0219.
33. Networking in rare cancers: What was done, what's next. **Frezza AM**, Trama A, Blay JY, Casali PG. *Eur J Surg Oncol*. 2019 Jan;45(1):16-18. doi: 10.1016/j.ejso.2018.03.030.
34. Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review. Raimondi A, Colombo F, Pintarelli G, Morosi C, Renne SL, **Frezza AM**, Saponara M, Dei Tos AP, Mazzocchi A, Provenzano S, Casali PG, Stacchiotti S. *Anticancer Drugs*. 2018 Jul;29(6):589-595. doi: 10.1097/CAD.0000000000000634.
35. Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre: Should Radiotherapy Still be a Standard? Fiore M, Ford S, Callegaro D, Sangalli C, Colombo C, Radaelli S, **Frezza AM**, Renne SL, Casali PG, Gronchi A. *Ann Surg Oncol*. 2018 Jun;25(6):1536-1543. doi: 10.1245/s10434-018-6393-x.
36. Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting. **Frezza AM**, Stacchiotti S, Gronchi A. *BMC Med*. 2017 Aug 22;15(1):160. doi: 10.1186/s12916-017-0931-4.
37. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. **Frezza AM**, Stacchiotti S, Gronchi A. *BMC Med*. 2017 Jun 2;15(1):109. doi: 10.1186/s12916-017-0872-y.
38. Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. Palassini E, **Frezza AM**, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, Morosi C, Collini P, Stacchiotti S, Casali PG, Gronchi A. *Cancer J*. 2017 Mar/Apr;23(2):86-91. doi: 10.1097/PPO.0000000000000254.
39. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, **Frezza AM**, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G. *Ann Oncol*. 2017 Nov 1;28(11):2906. doi: 10.1093/annonc/mdw551.
40. Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials. Galdy S, Cella CA, Spada F, Murgioni S, **Frezza AM**, Ravenda SP, Zampino MG, Fazio N. *Crit Rev Oncol Hematol*. 2016 Mar;99:1-12. doi: 10.1016/j.critrevonc.2015.09.004.
41. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Vincenzi B, Nannini M, Fumagalli E, Bronte G, **Frezza AM**, De Lisi D, Spalato Ceruso M, Santini D, Badalamenti G, Pantaleo MA, Russo A, Dei Tos AP, Casali P, Tonini G. *Oncotarget*. 2016 Oct 25;7(43):69412-69419. doi: 10.18632/oncotarget.5136.
42. Successful palliative approach with high-intensity focused ultrasound in a patient with metastatic anaplastic pancreatic carcinoma: a case report. Ungaro A, Orsi F, Casadio C, Galdy S, Spada F, Cella CA, Tonno CD, Bonomo G, Vigna PD, Murgioni S, **Frezza AM**, Fazio N. *Ecancermedicalsecience*. 2016 Apr 21;10:635. doi: 10.3332/ecancer.2016.635.
43. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. Vincenzi B, Stumbo L, Maltese G, Cerbone L, Spalato Ceruso M, Badalamenti G, Santini D, Tonini G, **Frezza AM**, De Lisi D, Sillelta M. *Sci Rep*. 2015 Aug 3;5:12077. doi: 10.1038/srep12077.
44. Primary cutaneous and subcutaneous Ewing sarcoma. Di Giannatale A, **Frezza AM**, Le Deley MC, Marec-Bérard P, Benson C, Blay JY, Bui B, Judson I, Oberlin O, Whelan J, Gaspar N. *Pediatr Blood Cancer*. 2015 Sep;62(9):1555-61. doi: 10.1002/pbc.25535.
45. Classic Kaposi Sarcoma: to treat or not to treat? Vincenzi B, D'Onofrio L, **Frezza AM**, Grasso RF, Fausti V, Santini D, Dei Tos AP, Tonini G. *BMC Res Notes*. 2015 Apr 10;8:138. doi: 10.1186/s13104-015-1076-1
46. Deregulation of dicer and mir-155 in liposarcoma. Vincenzi B, Iuliani M, Zoccoli A, Pantano F, Fioramonti M, De Lisi D, **Frezza AM**, Rabitti C, Perrone G, Onetti Muda A, Russo A, Giordano A, Santini D, Dei Tos AP, Tonini G. *Oncotarget*. 2015 Apr 30;6(12):10586-91. doi: 10.18632/oncotarget.3201.
47. Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. Venditti O, De Lisi D, Caricato M, Caputo D, Capolupo GT, Taffon C, Pagliara E, Battisti S, **Frezza AM**, Onetti Muda A, Tonini G. *BMC Cancer*. 2015 Mar 1;15:87. doi: 10.1186/s12885-015-1074-7.

48. Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. **Frezza AM**, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, Casanova J, Esler C, Ferrari S, Funovics PT, Gerrand C, Grimer R, Gronchi A, Haffner N, Hecker-Nolting S, Höller S, Jeys L, Jutte P, Leithner A, San-Julian M, Thorkildsen J, Vincenzi B, Windhager R, Whelan J. *Eur J Cancer*. 2015 Feb;51(3):374-81. doi: 10.1016/j.ejca.2014.11.007.
49. Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. **Frezza AM**, Benson C, Judson IR, Litiere S, Marreaud S, Sleijfer S, Blay JY, Dewji R, Fisher C, van der Graaf W, Hayward L. *Clin Sarcoma Res*. 2014 Jul 29;4:7. doi: 10.1186/2045-3329-4-7.
50. Lung nodule and functional changes in smokers after smoking cessation short-term treatment. Maci E, Comito F, **Frezza AM**, Tonini G, Pezzuto A. *Cancer Invest*. 2014 Oct;32(8):388-93. doi: 10.3109/07357907.2014.919308.
51. Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy. Fernanda Amary M, Ye H, Berisha F, Khatri B, Forbes G, Lehovsky K, **Frezza AM**, Behjati S, Tarpey P, Pillay N, Campbell PJ, Tirabosco R, Presneau N, Strauss SJ, Flanagan AM. *Cancer Med*. 2014 Aug;3(4):980-7. doi: 10.1002/cam4.268.
52. Trabectedin for desmoplastic small round cell tumours: a possible treatment option? **Frezza AM**, Whelan JS, Dileo P. *Clin Sarcoma Res*. 2014 Apr 25;4:3. doi: 10.1186/2045-3329-4-3.
53. Is [F-18]fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment? **Frezza AM**, Beale T, Bomanji J, Jay A, Kalavrezos N, Dileo P, Whelan J, Strauss SJ. *BMC Cancer*. 2014 Jan 15;14:23. doi: 10.1186/1471-2407-14-23.
54. Systemic therapy for rare tumours of the skin and soft tissue tumour. Vincenzi B, **Frezza AM**, Santini D, Tonini G. *Skin Cancer: A Practical Approach* 1 January 2014, Pages 475-485
55. Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients? Santini D, Vincenzi B, Venditti O, Dell'Aquila E, **Frezza AM**, Silletta M, Guida FM, Grasso RF, Silvestris N, Lanzetta G, Tonini G. *Future Oncol*. 2013 Dec;9(12):1809-11. doi: 10.2217/fon.13.170.
56. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. Tonini G, Imperatori M, Vincenzi B, **Frezza AM**, Santini D. *J Exp Clin Cancer Res*. 2013 Nov 18;32(1):92. doi: 10.1186/1756-9966-32-92.
57. Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. Vincenzi B, **Frezza AM**, Schiavon G, Santini D, Dileo P, Silletta M, Delisi D, Bertoldo F, Badalamenti G, Baldi GG, Zovato S, Berardi R, Tucci M, Silvestris F, Dei Tos AP, Tirabosco R, Whelan JS, Tonini G. *Clin Sarcoma Res*. 2013 Apr 17;3(1):6. doi: 10.1186/2045-3329-3-6.
58. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfex IV. Vincenzi B, **Frezza AM**, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V, Graziano F, Santini D, Tonini G. *Support Care Cancer*. 2013 May;21(5):1313-9. doi: 10.1007/s00520-012-1667-5.
59. Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. Vincenzi B, Silletta M, Schiavon G, **Frezza AM**, Del Vecovo R, Zobel BB, Santini D, Dei Tos AP, Tonini G. *Expert Opin Investig Drugs*. 2013 Jan;22(1):1-7. doi: 10.1517/13543784.2013.742886.
60. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, **Frezza AM**, Berti P, Tonini G. *Lancet Oncol*. 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X.
61. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, **Frezza AM**, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G. *Ann Oncol*. 2012 Sep;23(9):2313-2318. doi: 10.1093/annonc/mdr623.
62. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside. Vincenzi B, Napolitano A, D'Onofrio L, **Frezza AM**, Silletta M, Venditti O, Santini D, Tonini G. *Expert Opin Investig Drugs*. 2011 Dec;20(12):1685-705. doi: 10.1517/13543784.2011.628984.
63. PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/anthracycline-based first line therapy. Vincenzi B, Santini D, Schiavon G, **Frezza AM**, Silletta M, Crucitti P, Casali P, Dei Tos AP, Rossi S, Rizzo S, Badalamenti G, Tomasino RM, Russo A, Butrynski JE, Tonini G. *J Cell Physiol*. 2012 Apr;227(4):1657-62. doi: 10.1002/jcp.22889.
64. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. Vincenzi B, Santini D, Perrone G, Graziano F, Loupakis F, Schiavon G, **Frezza AM**, Ruzzo AM, Rizzo S, Crucitti P, Galluzzo S, Zoccoli A, Rabitti C, Muda AO, Russo A, Falcone A, Tonini G. *J Cell Physiol*. 2012 Mar;227(3):927-33. doi: 10.1002/jcp.22801.
65. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Vincenzi B, Santini D, **Frezza AM**, Berti P, Vespasiani U, Picardi A, Tonini G. *Expert Opin Drug Saf*. 2011 May;10(3):345-9. doi: 10.1517/14740338.2011.562888.
66. The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. Vincenzi B, Daniele S, **Frezza AM**, Berti P, Vespasiani U, Picardi A, Tonini G. *Support Care Cancer*. 2012 Jan;20(1):135-9. doi: 10.1007/s00520-010-1078-4.
67. Target therapy in gastrointestinal tract sarcoma: What is new? Vincenzi B, **Frezza AM**, Santini D, Tonini G. *World J Gastrointest Oncol*. 2010 Jan 15;2(1):1-4. doi: 10.4251/wjgo.v2.i1.1.
68. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives. Vincenzi B, Napolitano A, **Frezza AM**, Schiavon G, Santini D, Tonini G. *Pharmacogenomics*. 2010 Jun;11(6):865-78. doi: 10.2217/pgs.10.69.
69. New therapies in soft tissue sarcoma. Vincenzi B, **Frezza AM**, Santini D, Tonini G. *Expert Opin Emerg Drugs*. 2010 Jun;15(2):237-48. doi: 10.1517/14728211003592108.
70. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, **Frezza AM**, Caraglia M, Colucci G, Del Prete S, Tonini G. *Oncologist*. 2010;15(1):85-92. doi: 10.1634/theoncologist.2009-0143.
71. Docetaxel induced pericardial effusion. Vincenzi B, Santini D, **Frezza AM**, Rocci L, Tonini G. *J Exp Clin Cancer Res*. 2007 Sep;26(3):417-20.

## ORAL PRESENTATIONS

1. **“Ultra-rare sarcomas: how do we make progress?”**. ESMO “Sarcoma & GIST”, virtual, Jan 2022
2. **“Rare soft tissue and bone sarcomas”**. 5th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers, online, Dec 2021
3. **“Studio clinico ISG: EpisObs: studio osservazionale nel sarcoma epiteloide”**. Italian Sarcoma Group Journal Club, virtual, Sep 2021
4. **“Aggiornamento studi clinici nei sarcomi dell’osso e dei tessuti molli”**. Italian Sarcoma Group Annual Meeting, online, Dec 2020
5. **“An educational pathway on rare adult solid cancers”**. 5th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers, online, Dec 2020
6. **“Bone sarcomas: clinical case discussion”**. Connective Tissue Oncology Society, evento online, Nov 2020
7. **“Systemic therapies in advanced epithelioid haemangioendothelioma (EHE): a retrospective international series within the World Sarcoma Network**. ESMO Annual Meeting. Online event. Sep 2020.
8. **“Medicina di precisione nei sarcomi”**. Online webinar. Università Campus Bio-Medico di Roma, Jun 2020
9. **“The challenging model of epithelioid sarcoma”**. ESMO “Sarcoma & GIST”, Milano, Feb 2020
10. **“Networking in rare cancers”**. 4th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers, Milano, Dec 2019
11. **“Un’esperienza pratica di multidisciplinarietà: i sarcomi dei tessuti molli”**. ONCONVENTIONAL Journey. Milano, Dec 2019.
12. **“Trattamento della malattia localizzata”**. Corso ECM “Approccio Multidisciplinare ai sarcomi dei tessuti molli”. Roma, Sep 2019.
13. **“Histiocytic/ dendritic cell neoplasms”**. ESO Post-graduate Course “Clinical Oncology: Sarcomas”, Inveruno, Jul 2019
14. **“Sarcomi e tumori rari: nuove possibilità terapeutiche nella malattia □avanzata”**. Master di 2° livello in cure palliative, Fondazione IRCCS Istituto Nazionale Tumori. Milano, Jan 2019.
15. **“Systemic treatments in MDM2 positive intimal sarcoma: a multicentre experience with anthracycline, gemcitabine and pazopanib within the World Sarcoma Network (WSN).”** Connective Tissue Oncology Society, Roma, Nov 2018
16. **“JC. Soft tissue sarcoma”**. Italian Sarcoma Group, Palermo, Apr 2018
17. **“Sarcomi dell’osso e dei tessuti molli”**. Collegio degli Oncologi Medici Universitari, riunione nazionale, Torino, Feb 2018
18. **“Histiocytic/ dendritic cell neoplasms”**. ESMO Preceptorship Course “Sarcoma & GIST”, Milano, Feb 2018
19. **“The EU initiatives: EURACAN and the European Reference Networks”**. University Post-graduate Course “Clinical Oncology: Sarcomas”, Milano, Jan 2018
20. **“La European Reference Network (EURACAN e dintorni) e la Joint Action on Rare Cancers (JARC)”**. Grandangolo in Oncologia XIX edizione, Genova, Dec 2017
21. **“Histiocytic/ dendritic cell neoplasms”**. 2nd ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers, Milano, Dec 2017
22. **Cancer: some definitions”**. 2nd ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers, Milano, Dec 2017
23. **“Anthracycline, gemcitabine and pazopanib in epithelioid sarcoma: results of a retrospective multi-institutional case series”**. Connective Tissue Oncology Society, Maui, Nov 2017
24. **“Sarcomi ossei”**. Sarcomi: the best of CTOS and ESMO (Accademia Nazionale di Medicina), Nov 2017:
25. **“JC. Soft tissue sarcoma”**. Italian Sarcoma Group, Napoli, Apr 2017
26. **“PEComi: cosa fare?”**. Rete Oncologica del Veneto per i Sarcomi: problematiche aperte, Padova, Dec 2016
27. **“Desmoplastic small round cell tumour: what has been tried?”**. Connective Tissue Oncology Society, Lisbona, Nov 2016
28. **“Novità in tema di sarcomi”**, Associazione Italiana di Oncologia Medica Giovani, Jul 2016
29. **“Sarcomi dei Tessuti Molli: studi clinici in corso”**. Italian Sarcoma Group, Roma, Apr 2016
30. **“Le neoplasie neuroendocrine”**. Associazione Italiana di Oncologia Medica Giovani Giovani, Perugia, Jul 2015
31. **“Diagnosi e stadiazione nelle neoplasie neuroendocrine”**. “La pratica clinica nelle Neoplasie Neuroendocrine Enteropancreatiche”. IEO Milano, Apr 2015
32. **“Mesenchymal chondrosarcoma: prognostic factors and outcome. An EMSOS study”**. European Muskulo-Skeletal Oncology Society Annual Meeting, Vienna, May 2014
33. **“Superficial Ewing Sarcoma: a retrospective analysis of 20 patients”**. Associazione Italiana Oncologia Medica, meeting annuale, Roma, Oct 2013
34. **“Pazopanib in soft tissue sarcoma: a snapshot from everyday clinical practice”**. British sarcoma Group annual meeting, Nottingham, Feb 2013
35. **“Superficial Ewing Sarcoma: a retrospective analysis of 20 patients”**. British sarcoma Group annual meeting, Nottingham, Feb 2013
36. **“Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?”**. European Muskulo-Skeletal Oncology Society Annual Meeting, Bologna, May 2012



## POSTERS (SELECTION)

1. **“An epidemiological insight into epithelioid sarcoma (ES): the open issue of distal-type (DES) versus proximal-type (PES)”**. ESMO 2017 Congress, Madrid, September 2017
2. **“Imatinib in combination with everolimus in patients with progressive advanced chordoma: results form an Italian phase 2 clinical trial”**. ESMO 2017 Congress, Madrid, September 2017
3. **“Anthracycline, gemcitabine and pazopanib in epithelioid sarcoma: results of a retrospective multi-institutional case series”**. American Society of Clinical Oncology Annual Meeting, Chicago, Giugno 2017
4. **“Pleomorphic rhabdomyosarcoma: single institution experience”**. Connective Tissue Oncology Society, Lisbona, Novembre 2016
5. **“Safety and efficacy of pazopanib in advanced desmoplastic small round cell tumour: retrospective analysis of a multi-institutional experience”**. Connective Tissue Oncology Society, New York, Novembre 2013
6. **“Cutaneous and Subcutaneous Ewing Sarcoma: Epidemiology, Treatment and outcome”**. Connective Tissue Oncology Society, New York, Novembre 2013  
**“Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience”**. European Muskulo-Skeletal Oncology Society Annual Meeting, Bologna, Maggio 2012

## AWARDS

1. Fondazione IRCCS Istituto Nazionale dei Tumori – 2019: **“Premio Giovani Ricercatori 2018”**
2. European Society of Medical Oncology – 2017: winner of the fellowship **“Leaders Generation Programme 2017”**
3. Fondazione Umberto Veronesi – 2015: winner of **“Annual research grant”**
4. European Neuroendocrine Tumour Society – 2015: winner of **“ENETS CoE Training Fellowship”**
5. European Muskulo-Skeletal Oncology Society – 2014 – **“Best Paper Award”**: **“Mesenchymal chondrosarcoma: prognostic factors and outcome. An EMSOS study”**.